1. Clinical Case Scenarios
IMPAACT 2010/VESTED Study-Specific Training May 2017

2. Protocol References Section Title Section 7
Safety Assessment, Monitoring, and Reporting
Section 8
Participant Management
Appendix II
Maternal Toxicity Management Guidelines

3. Scenario 1
Consider a 20 year old pregnant woman who tested HIV-positive when presenting for antenatal care on 1 August 2017 and was then referred for possible participation in IMPAACT 2010.

4. At screening, on 3 August 2017, this woman reports a history of asthma since childhood. She does not routinely take medication for this condition, but she has an inhaler that she uses when needed. She has had some nausea during the current pregnancy. This has been occurring less often recently, but still occurs from time to time. The nausea has not been accompanied by vomiting. Her screening laboratory results identify a grade 1 hemoglobin level; all other test results are normal.
Based on the brief description provided here, what additional information will the study clinician need to probe for to adequately source document this participant’s pre-existing medical conditions?

5. At screening, on 3 August 2017, this woman reports a history of asthma since childhood. She does not routinely take medication for this condition, but she has an inhaler that she uses when needed. She has had some nausea during the current pregnancy. This has been occurring less often recently, but still occurs from time to time. The nausea has not been accompanied by vomiting. Her screening laboratory results identify a grade 1 hemoglobin level; all other test results are normal.
(2) Assuming this woman is enrolled in the study, what conditions would need to be entered into the Medical History eCRF (if any)?

6. At screening, on 3 August 2017, this woman reports a history of asthma since childhood. She does not routinely take medication for this condition, but she has an inhaler that she uses when needed. She has had some nausea during the current pregnancy. This has been occurring less often recently, but still occurs from time to time. The nausea has not been accompanied by vomiting. Her screening laboratory results identify a grade 1 hemoglobin level; all other test results are normal.
(3) What updates of this participant’s baseline history would need to be source documented? What new data would need to be entered into eCRFs (if any)?

7. At antepartum Week 12, this participant reports a history of nausea, vomiting, and diarrhea which started two days ago. She has not taken her temperature but reports periods of feeling hot and having intermittent chills. Her husband has had similar symptoms for the past three days. She has not been able to perform her usual household tasks or eat solid food, but has been able to tolerate small amounts of tea. The study clinician notes that the participant appears unwell and has an axillary measured fever of 39.2 C. Her blood pressure is 130/92.
(4) Based on the brief description provided here, what would your differential diagnosis include for this participant’s reported symptoms?

8. At antepartum Week 12, this participant reports a history of nausea, vomiting, and diarrhea which started two days ago. She has not taken her temperature but reports periods of feeling hot and having intermittent chills. Her husband has had similar symptoms for the past three days. She has not been able to perform her usual household tasks or eat solid food, but has been able to tolerate small amounts of tea. The study clinician notes that the participant appears unwell and has an axillary measured fever of 39.2 C. Her blood pressure is 130/92.
(5) How would you manage this participant clinically? What additional evaluations would you perform at the Week 12 visit (if any)? Would your management involve any changes of ARVs? What would your follow-up plan be?

9. At antepartum Week 12, this participant reports a history of nausea, vomiting, and diarrhea which started two days ago. She has not taken her temperature but reports periods of feeling hot and having intermittent chills. Her husband has had similar symptoms for the past three days. She has not been able to perform her usual household tasks or eat solid food, but has been able to tolerate small amounts of tea. The study clinician notes that the participant appears unwell and has an axillary measured fever of 39.2 C. Her blood pressure is 130/92.
(6) What conditions would need to be entered into Adverse Event eCRFs (if any)?

10. Scenario 2
Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later.
The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry.
At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN.

11. Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later. The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry. At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN. What grade is this laboratory value?
Grade 1
Grade 2
Grade 3
Grade 4
0 of 0

12. Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later. The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry. At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN. What grade is this laboratory value?

13. Repeat ALT/AST within 3-4 business days
Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later. The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry. At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN. What management action would you take based on this result?
Repeat ALT/AST within 3-4 business days
Check for signs of clinical hepatitis
Check total and direct bilirubin
All of the above
0 of 0

14. Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later. The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry. At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN. At the follow-up visit, she confirms she had no symptoms and her repeat labs confirm the initial Grade 2 ALT result. Should you inform the CMC?
Yes No
0 of 0

15. Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later. The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry. At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN. At the follow-up visit, she confirms she had no symptoms and her repeat labs confirm the initial Grade 2 ALT result. What management action would you take based on this result?

16. Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later. The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry. At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN. How would your management change if the woman reported vomiting and malaise at her Week 14 postpartum visit?

17. Consider a woman who enters IMPAACT 2010 at 27 weeks gestation and delivers 12 weeks later. The mother was randomized to Arm 3, EFV/3TC/TDF, which she began at Entry. At Week 14 postpartum, she was clinically well. However, her ALT result returned at 4.5 x ULN. How would your management change if the woman reported vomiting and malaise at her Week 14 postpartum visit?